Silk Road Medical, Inc (SILK)
NASDAQ: SILK · IEX Real-Time Price · USD
16.98
-0.59 (-3.36%)
Apr 25, 2024, 12:17 PM EDT - Market open
Silk Road Medical Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Silk Road Medical stock have an average target of 23.9, with a low estimate of 8.00 and a high estimate of 55. The average target predicts an increase of 40.75% from the current stock price of 16.98.
Analyst Consensus: Buy
* Price targets were last updated on Mar 7, 2024.
Analyst Ratings
The average analyst rating for SILK stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 3 | 3 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 7 | 7 | 6 | 6 | 5 | 5 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 11 | 11 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Argus Research | Argus Research | Hold → Strong Buy Upgrades $24 | Hold → Strong Buy | Upgrades | $24 | +41.34% | Mar 7, 2024 |
| Stifel | Stifel | Strong Buy Maintains $20 → $23 | Strong Buy | Maintains | $20 → $23 | +35.45% | Feb 29, 2024 |
| JP Morgan | JP Morgan | Hold Maintains $10 → $19 | Hold | Maintains | $10 → $19 | +11.90% | Feb 29, 2024 |
| Piper Sandler | Piper Sandler | Hold Maintains $11 → $18 | Hold | Maintains | $11 → $18 | +6.01% | Feb 29, 2024 |
| Stifel | Stifel | Hold → Strong Buy Upgrades $9 → $20 | Hold → Strong Buy | Upgrades | $9 → $20 | +17.79% | Jan 19, 2024 |
Financial Forecast
Revenue This Year
199.84M
from 177.13M
Increased by 12.82%
Revenue Next Year
222.15M
from 199.84M
Increased by 11.16%
EPS This Year
-1.42
from -1.44
EPS Next Year
-1.32
from -1.42
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 206.5M | 236.7M | 260.4M | 299.5M |
| Avg | 199.8M | 222.2M | 245.1M | 290.9M |
| Low | 190.1M | 208.7M | 225.4M | 279.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 16.6% | 18.4% | 17.2% | 22.2% |
| Avg | 12.8% | 11.2% | 10.3% | 18.7% |
| Low | 7.3% | 4.5% | 1.5% | 14.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -1.39 | -1.23 | -0.91 | -1.24 |
| Avg | -1.42 | -1.32 | -1.26 | -1.20 |
| Low | -1.47 | -1.54 | -1.58 | -1.16 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | - |
| Avg | - | - | - | - |
| Low | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.